Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in:

Open Access 01-12-2024 | Research

TMSB4X is a regulator of inflammation-associated ferroptosis, and promotes the proliferation, migration and invasion of hepatocellular carcinoma cells

Authors: Linlin Tang, Yangli Jin, Jinxu Wang, Xiuyan Lu, Mengque Xu, Mingwei Xiang

Published in: Discover Oncology | Issue 1/2024

Login to get access

Abstract

Background

Ferroptosis and inflammation are involved in cancer progression. The aim of this study was to identify inflammation-associated ferroptosis regulators in hepatocellular carcinoma (HCC).

Methods

FerrDb database was searched for ferroptosis-related genes. RNA sequencing data and clinicopathologic information of HCC patients were downloaded from the Cancer Genome Atlas (TCGA) database. Weighted gene co-expression network analysis was applied to obtain the genes probably involved in inflammation-associated ferroptosis. Univariate Cox regression analysis was conducted to screen prognostic genes, and 10 machine learning algorithms were combined to find the optimal strategy to evaluate the prognosis of the patients based on the prognosis-related genes. The patients were divided into high risk group and low risk group, and the differentially expressed genes were obtained. Thymosin beta 4 X-linked (TMSB4X) was overexpressed or knocked down in HCC cell lines, and then qPCR, CCK-8, Transwell, flow cytometery assays were performed to detect the change of HCC cells’ phenotypes, and Western blot was used to detect the change of ferroptosis markers.

Results

157 genes related to inflammation and ferroptosis in HCC were obtained by WGCNA. rLasso algorithm, with the highest C-index, screened out 29 hub genes, and this model showed good efficacy to predict the prognosis of HCC patients. The patients in high risk group and low risk groups showed distinct molecular characteristics. TMSB4X was the most important gene which dominated the classification, and it was highly expressed in HCC samples. TMSB4X promoted the viability, migration and invasion, and repressed ferroptosis of HCC cells.

Conclusion

The risk model constructed based on the inflammation-associated ferroptosis regulators is effective to predict the clinical outcome of HCC patients. TMSB4X, involved in inflammation-associated ferroptosis, is a potential biomarker and therapeutic target for HCC.
Literature
1.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.PubMedCrossRef
2.
Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the Global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–91.PubMedPubMedCentralCrossRef
3.
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.PubMedPubMedCentralCrossRef
4.
Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.PubMedCrossRef
5.
Tan DJH, Wong C, Ng CH, et al. A meta-analysis on the rate of hepatocellular carcinoma recurrence after liver transplant and associations to etiology Alpha-Fetoprotein, Income and Ethnicity. J Clin Med. 2021;10(2):238.PubMedPubMedCentralCrossRef
6.
EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef
7.
Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72(2):342–52.PubMedCrossRef
8.
Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71(3):543–52.PubMedCrossRef
9.
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96.PubMedCrossRef
10.
11.
12.
13.
Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7(1):196.PubMedPubMedCentralCrossRef
14.
Ajoolabady A, Tang D, Kroemer G, Ren J. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy. Br J Cancer. 2023;128(2):190–205.PubMedCrossRef
15.
16.
Hao X, Zheng Z, Liu H, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56:102463.PubMedPubMedCentralCrossRef
17.
Chen Q, Zheng W, Guan J, et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2023;30(1):137–51.PubMedCrossRef
18.
Zhao L, Zhou X, Xie F, et al. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun. 2022;42(2):88–116.CrossRef
19.
20.
Ruan W, Zhang L, Lei S, et al. An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma. J Cell Mol Med. 2023;27(13):1820–35.PubMedPubMedCentralCrossRef
21.
Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.PubMedCrossRef
22.
Sharma A, Flora SJS. Positive and negative regulation of ferroptosis and its role in maintaining metabolic and redox homeostasis. Oxid Med Cell Longev. 2021;2021:9074206.PubMedPubMedCentralCrossRef
23.
Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: the growing challenge. Hepatology. 2023;77(1):323–38.PubMedCrossRef
24.
25.
26.
27.
Taghehchian N, Maharati A, Akhlaghipour I, Zangouei AS, Moghbeli M. PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression. Cancer Cell Int. 2023;23(1):233.PubMedPubMedCentralCrossRef
28.
Lu Y, Qin H, Jiang B, et al. KLF2 inhibits cancer cell migration and invasion by regulating ferroptosis through GPX4 in clear cell renal cell carcinoma. Cancer Lett. 2021;522:1–13.PubMedCrossRef
29.
Li Y, Tu S, Zeng Y, et al. KLF2 inhibits TGF-β-mediated cancer cell motility in hepatocellular carcinoma. Acta Biochim Biophys Sin. 2020;52(5):485–94.PubMedCrossRef
30.
Chen XQ, Ma J, Xu D, Xiang ZL. Comprehensive analysis of KLF2 as a prognostic biomarker associated with fibrosis and immune infiltration in advanced hepatocellular carcinoma. BMC Bioinform. 2023;24(1):270.CrossRef
31.
32.
He GN, Bao NR, Wang S, et al. Ketamine induces ferroptosis of liver cancer cells by targeting lncRNA PVT1/miR-214-3p/GPX4. Drug Des Dev Ther. 2021;15:3965–78.CrossRef
33.
Wu MN, Zhou DM, Jiang CY, et al. Genetic analysis of potential biomarkers and therapeutic targets in ferroptosis from psoriasis. Front Immunol. 2022;13:1104462.PubMedCrossRef
34.
Chen W, Yang Z, Chen Y. A novel oxidative phosphorylation-associated gene signature for prognosis prediction in patients with hepatocellular carcinoma. Dis Markers. 2022;2022:3594901.PubMedPubMedCentralCrossRef
35.
Mittler R, Darash-Yahana M, Sohn YS, et al. NEET proteins: a new link between iron metabolism, reactive oxygen species, and cancer. Antioxid Redox Signal. 2019;30(8):1083–95.PubMedPubMedCentralCrossRef
36.
37.
Lu T, Li C, Xiang C, Gong Y, Peng W, Chen C. Overexpression of CISD1 predicts worse survival in hepatocarcinoma patients. Biomed Res Int. 2022;11(2022):7823191.
38.
39.
Shomali N, Baradaran B, Deljavanghodrati M, et al. A new insight into thymosin β4, a promising therapeutic approach for neurodegenerative disorders. J Cell Physiol. 2020;235(4):3270–9.PubMedCrossRef
40.
Chi LH, Chang WM, Chang YC, et al. Global proteomics-based identification and validation of thymosin beta-4 X-linked as a prognostic marker for head and neck squamous cell carcinoma. Sci Rep. 2017;7(1):9031.PubMedPubMedCentralCrossRef
41.
Zhang X, Han J, Fan D, et al. Lysine-40 succinylation of TAGLN2 induces glioma angiogenesis and tumor growth through regulating TMSB4X. Cancer Gene Ther. 2023;30(1):172–81.PubMedCrossRef
42.
Kuo CY, Jhuang JY, Huang WC, Cheng SP. Aberrant expression of thymosin beta-4 correlates with advanced disease and BRAF V600E mutation in thyroid cancer. J Histochem Cytochem. 2022;70(10):707–16.PubMedPubMedCentralCrossRef
43.
Makowiecka A, Mazurkiewicz E, Mrówczyńska E, et al. Changes in biomechanical properties of A375 cells due to the silencing of TMSB4X expression are not directly correlated with alterations in their stemness features. Cells. 2021;10(4):769.PubMedPubMedCentralCrossRef
44.
45.
Wang Z, Wu L, Zhou Y, et al. Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. Front Pharmacol. 2024;15:1394241.PubMedPubMedCentralCrossRef
Metadata
Title
TMSB4X is a regulator of inflammation-associated ferroptosis, and promotes the proliferation, migration and invasion of hepatocellular carcinoma cells
Authors
Linlin Tang
Yangli Jin
Jinxu Wang
Xiuyan Lu
Mengque Xu
Mingwei Xiang
Publication date
01-12-2024
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-024-01558-0

Other articles of this Issue 1/2024

Decreased mitochondrial transcription factor A and mitochondrial DNA copy number promote cyclin-dependent kinase inhibitor 1A expression and reduce tumorigenic properties of colorectal cancer cells

  • Open Access
  • Research

Circular RNA COL1A1 promotes Warburg effect and tumor growth in nasopharyngeal carcinoma

  • Open Access
  • Research

CT and MR imaging characteristics of primary hepatic lymphoma

Unraveling the causal association between lifestyle and metabolic factors with endometrial cancer: evidence from a Mendelian randomization study

Immune-oncology targets and therapeutic response of cell pyroptosis-related genes with prognostic implications in neuroblastoma

  • Open Access
  • Analysis

Identification and validation of a novel prognostic signature and key genes related to development of anaplastic thyroid carcinoma

  • Open Access
  • Research

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits